α-L-iduronidase therapy for mucopolysaccharidosis type I
Jakub Tolar, Paul J OrchardDivision of Hematology, Oncology, Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USAAbstract: More than 500 patients with mucopolysaccharidosis type IH (MPS IH; Hurler syndrome) have been treated with hematopoietic cel...
Guardado en:
Autores principales: | Jakub Tolar, Paul J Orchard |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9a9279cbf5c7416fa17f0e5b6100c728 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Mesenchymal stem cells do not prevent antibody responses against human α-L-iduronidase when used to treat mucopolysaccharidosis type I.
por: Priscila Keiko Matsumoto Martin, et al.
Publicado: (2014) -
Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
por: Fraga M, et al.
Publicado: (2017) -
α-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy
por: Jungyeon Hwang, et al.
Publicado: (2008) -
Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy
por: Huan Xie, et al.
Publicado: (2011) -
Molecular Analysis of Vietnamese Patients with Mucopolysaccharidosis Type I
por: Ngoc Thi Bich Can, et al.
Publicado: (2021)